Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New smart scale could keep dialysis patients out of the ER

NCT ID NCT07059962

Disease control Sponsor: Bodyport Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a special scale that measures heart signals and fluid levels in people on peritoneal dialysis for kidney failure. The goal is to see if the scale can warn patients and doctors early when fluid overload is about to happen, so they can take action before an emergency visit or hospital stay. About 125 adults will use the scale at home for up to 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bodyport Cardiac Scale (a smart scale that measures heart and fluid status)
What this could lead to
If it works, this scale could help people on peritoneal dialysis avoid dangerous fluid buildup and reduce emergency hospital visits.
What could go wrong
This is an early study with only 125 participants. The scale may not accurately predict problems for everyone, and false alerts could cause unnecessary worry.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 125 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Males and females 21 years of age or older, with end stage kidney disease undergoing peritoneal dialysis.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 21 years or older 2. Able to speak and read English, or able to speak and read Spanish and has a caregiver or family member who speaks English and can provide assistance 3. Able to stand on two bare feet unassisted 4. Receiving automated peritoneal dialysis for the treatment of ESKD 5. Followed on the Vantive Sharesource Remote Patient Management Platform Exclusion Criteria: 1. Undergoing or plan to undergo hemodialysis in the next 12 months 2. Have a life expectancy of less than 12 months 3. Are pregnant or plan to become pregnant during the next 12 months 4. Weigh greater than 375 lbs 5. Planned kidney transplant within the next 12 months 6. Have an implanted neurostimulator system

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End stage kidney disease (ESRD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease Edema end stage renal failure heart failure impaired renal function disease kidney disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End stage kidney disease (ESRD) Kidney disease Peritoneal dialysis (PD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Desert Cities Dialysis

    RECRUITING

    Victorville, California, 92395, United States

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60611, United States

  • Seven Oaks General Hospital

    RECRUITING

    Winnipeg, Manitoba, R2V 3M3, Canada

  • Southeastern Clinical Research Institute

    RECRUITING

    Augusta, Georgia, 30904, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.